表紙
市場調査レポート

IVD(体外診断)検査の世界市場

IVD (In Vitro Diagnostic) Testing World Markets

発行 TriMark Publications 商品コード 323346
出版日 ページ情報 英文 339 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
IVD(体外診断)検査の世界市場 IVD (In Vitro Diagnostic) Testing World Markets
出版日: 2015年01月01日 ページ情報: 英文 339 Pages
担当者のコメント
TriMark Publicationsは、診断検査の市場分析に定評のある調査会社です。米国ニューヨークに本社を置き、世界市場の中でもアメリカ市場の分析を得意としています。TriMark Publicationsが発行するレポートは、比較的短いスパンで情報が更新される商品が多く、最新データが網羅されているとして継続的に購入されるお客様が多い人気のシリーズです。
概要

当レポートでは、世界のIVD(体外診断)検査市場について調査し、世界および米国における主要部門の成長促進因子と阻害因子、売上額と市場成長率などを分析しており、診断技術の潜在的メリットに関する議論、多様なビジネスモデルの評価、および主要企業のプロファイルをまとめ、お届け致します。

第1章 IVD市場の概要

第2章 IVDの世界市場概要

  • 世界の総IVD市場
  • 世界市場・各国市場
  • IVD市場セグメント:検体別
  • 高成長市場
  • 主要企業
  • IVD産業における主要動向
  • 買収
  • 市場促進因子・障壁
  • コンパニオン診断

第3章 POCT(ポイントオブケア検査)

  • POCT市場の概要
  • POCT市場セグメント:検体別
  • 主要企業
  • POCT市場の主なコンセプト
  • POCTの将来
  • POCTにおける最大の新しい機会

第4章 分子診断

  • 市場概要
  • 市場規模・成長率
  • 主要企業
  • 市場セグメント
  • 分子診断産業構造のスナップショット
  • 分子診断検査の前進
  • 主要部門のまとめ

第5章 臨床化学

  • 市場概要
  • 国際市場
  • 主要企業
  • 市場区分
  • 長期的課題
  • 市場促進因子
  • 成長の制限
  • IVD市場における注目部門
  • 主要技術
  • 主要部門のまとめ

第6章 糖尿病・グルコース検査

  • 市場概要
  • グルコース自己検査市場
  • 主要企業
  • 患者自己検査の将来
  • ランセット市場
  • OTC・自己検査市場の促進因子
  • OTC検査の重要な要素
  • セルフモニタリング血糖市場の戦略的提言
  • 患者自己検査の将来

第7章 免疫化学市場

  • 概要
  • 免疫アナライザー検査市場
  • 主要企業
  • 長期的課題
  • 市場成長促進因子・阻害因子
  • 免疫アナライザー市場の注目部門
  • 主要技術
  • 主要部門のまとめ

第8章 血液学

  • 市場概要
  • 国際市場
  • 主要企業
  • 血液アナライザー
  • 利益性
  • 市場促進因子
  • 主要部門のまとめ

第9章 凝固

  • 市場概要
  • 世界市場
  • 主要企業
  • 近年の凝固検査部門における活動
  • 抗凝固自己検査・自己管理
  • 市場促進因子・阻害因子
  • 新しい経口抗凝固薬の凝固検査市場への影響
  • 主要技術
  • 主な戦略的提言

第10章 病理学

  • 概要
  • 病理学市場
  • 主要企業
  • デジタル病理学市場

第11章 微生物学

  • 概要
  • 顕微鏡検査
  • 微生物試薬の市場規模・収益分析
  • 主要企業
  • 感染症向け診断プラットフォーム
  • 感染症検査市場の市場促進因子・阻害因子
  • 主要部門のまとめ

第12章 血液バンキング・スクリーニング

  • 市場概要
  • 国際市場
  • 血液スクリーニングの主要企業

第13章 組織・細胞検査

  • 総市場
  • 市場促進因子
  • 市場阻害因子
  • 細胞・組織技術のプラットフォーム
  • 細胞スクリーニング手法・パップスメア技術
  • 組織

第14章 データ管理・接続

  • ワイヤレスLAN
  • 接続プラットフォーム
  • POCT接続のメリット
  • POCTアナライザー接続ソフトウェアソリューション

第15章 企業プロファイル

図表

目次
Product Code: TMRIVD15-0101

In vitro diagnostic (IVD) testing is experiencing a revival fueled by a combination of technological improvements, cost pressures, reimbursement changes, rapid growth in molecular diagnostics and increasing interest in the genomics testing. Recent advances in molecular diagnostics technologies-including sequencing, PCR and microarrays-are enabling greater sensitivity and precision in nucleic acid measurements, further expanding manufacturers' offerings. This TriMark Publications report is an overview of each major in vitro diagnostic testing segment, including: point of care testing (POCT), molecular diagnostics, chemistry, diabetes and glucose, immunoassay, hematology, coagulation, pathology, microbiology, histology and cytology, and blood banking. For each segment, this study examines the generally accepted clinical analytical activities in use today. Moreover, the analysis here discusses the potential benefits of the diagnostics techniques, as well as provides market size and future growth potential. Additionally, this report assesses the various business models, including CLIA-licensed specialty labs, general reference labs and reagent kit marketing. This study also examines hundreds of companies that are actively developing and marketing IVD testing products around the world. This report analyzes the size and growth of the important sectors of the diagnostics market, including the drivers and restraints that influence the various market segments, as well as the dollar volume of sales and market growth rates, both in the U.S. and worldwide.

Table of Contents

1. IVD Market Overview

  • 1.1. Statement of Report
  • 1.2. About This Report
  • 1.3. Scope of the Report
  • 1.4. Objectives
  • 1.5. Methodology
  • 1.6. Executive Summary

2. IVD Global Market Overview

  • 2.1. Total Global IVD Market
  • 2.2. International Sector and Country IVD Markets
  • 2.3. IVD Market Segments by Analyte
  • 2.4. High Growth Markets
    • 2.4.1. Summary Analysis of the Global IVD High-Growth Market by Geographic Region
      • 2.4.1.1. U.S.: Summary of IVD High-Growth Market
      • 2.4.1.2. Europe: Summary Analysis of the IVD High-Growth Market
      • 2.4.1.3. South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market
      • 2.4.1.4. BRIC: Summary Analysis of the IVD High-Growth Market
        • 2.4.1.4.1. Brazil: Summary Analysis of the IVD High-Growth Market
        • 2.4.1.4.2. Russia: Summary Analysis of the IVD High-Growth Market
        • 2.4.1.4.3. Indian IVD High Growth Markets
        • 2.4.1.4.4. Summary of IVD High-Growth Market India
        • 2.4.1.4.5. China: Summary Analysis of the IVD High-Growth Market
        • 2.4.1.4.6. Summary of IVD High-Growth Market China
  • 2.5. Key Players
  • 2.6. Key Trends in the IVD Industry
  • 2.7. Acquisitions
  • 2.8. Market Drivers and Barriers
    • 2.8.1. Key Market Drivers
    • 2.8.2. Barriers to Growth
  • 2.9. Companion Diagnostics

3. POCT

  • 3.1. POCT Market Overview
    • 3.1.1. Total Global POCT Market
    • 3.1.2. International Sector and Country POCT Markets
  • 3.2. POCT Market Segments by Analyte
  • 3.3. Key Players
    • 3.3.1. Acquisition, License Agreements, Internal Development and Partnerships
  • 3.4. Key Concepts for POCT Markets
  • 3.5. The Future of POCT
  • 3.6. The Biggest New Opportunities in POCT

4. Molecular Diagnostics

  • 4.1. Market Overview
  • 4.2. Market Size and Growth Rate
  • 4.3. Key Players
  • 4.4. Market Segments
    • 4.4.1. Infectious Disease
      • 4.4.1.1. Key Segments of Molecular Diagnostic Markets for Infectious Disease
    • 4.4.2. Cancer
      • 4.4.2.1. Technology and Market Trends in Cancer Testing
      • 4.4.2.2. Cancer Testing
      • 4.4.2.3. Cancer Prognostic Assays
      • 4.4.2.4. Market Size
      • 4.4.2.5. Key Players
      • 4.4.2.6. Competitive Landscape
        • 4.4.2.6.1. Myriad Genetics (BRCA1 and BRCA2)
        • 4.4.2.6.2. Genomic Health (Oncotype DX)
        • 4.4.2.6.3. InterGenetics, Inc.
        • 4.4.2.6.4. Clarient, Inc. (GE Healthcare)
        • 4.4.2.6.5. BioTheronostics
        • 4.4.2.6.6. Agendia B.V. (MammaPrint)
        • 4.4.2.6.7. LabCorp
        • 4.4.2.6.8. Quest Diagnostics
      • 4.4.2.7. Competitive Structure and Market Share Analysis
      • 4.4.2.8. Drivers and Restraints
        • 4.4.2.8.1. Molecular Diagnostics Cancer Market Drivers Ranked in Order of Impact
        • 4.4.2.8.2. Molecular Diagnostics Cancer Market Restraints Ranked in Order of Impact
      • 4.4.2.9. Business Factors Influencing Advanced Oncology Testing Services
      • 4.4.2.10. Market Trends in Cancer Testing
      • 4.4.2.11. Strategic Recommendations on Molecular Diagnostic Sector Business Functions
      • 4.4.2.12. Emerging Cancer Personalized Medicine Market
    • 4.4.3. Genetic Testing
      • 4.4.3.1. Genetic Testing Market
      • 4.4.3.2. Primary Competitors
      • 4.4.3.3. Prominent Issues in Genetic Prenatal Diagnosis Using Molecular Diagnostics Testing
  • 4.5. Snapshot of Molecular Diagnostics Industry Structure
    • 4.5.1. Technology and Market Trends
    • 4.5.2. Emerging Technologies
    • 4.5.3. Market Trends
  • 4.6. Molecular Diagnostics Testing Going Forward
  • 4.7. Key Sector Takeaways

5. Clinical Chemistry

  • 5.1. Market Overview
  • 5.2. International Markets
    • 5.2.1. U.S. Market
    • 5.2.2. European Market
    • 5.2.3. Asian Market
  • 5.3. Key Players
  • 5.4. Market Segments
    • 5.4.1. Ultra-Large Throughput Chemistry Analyzers
    • 5.4.2. Large Throughput Analyzers
    • 5.4.3. Mid-Size Clinical Chemistry Analyzers
    • 5.4.4. Chemistry Analyzers for the Small-Volume Market
  • 5.5. Long-Term Changes
  • 5.6. Market Drivers
  • 5.7. The Limits to Growth
  • 5.8. Hot Sectors in the IVD Market
  • 5.9. Key Technologies
  • 5.10. Key Sector Takeaways

6. Diabetes and Glucose Testing

  • 6.1. Market Overview
  • 6.2. Glucose Self-Testing Markets
  • 6.3. Key Players
    • 6.3.1. M&A Activity
    • 6.3.2. Important Deals in BGM Market
  • 6.4. Future of Patient Self-testing
  • 6.5. Lancet Market
    • 6.5.1. Market Size
    • 6.5.2. Strategic Recommendations in the Lancet Business
    • 6.5.3. Health and Safety Regulations
    • 6.5.4. Key Players in the Blood Lancet Market
    • 6.5.5. Lancet Distribution Networks
  • 6.6. Drivers of OTC and Self-testing Markets
    • 6.6.1. Factors Affecting OTC Medical Product Distribution
    • 6.6.2. Drugstores Critical to the Diabetic Care Category
  • 6.7. Important Elements of OTC Testing
  • 6.8. Strategic Recommendations for Self-Monitoring Blood Glucose Markets
  • 6.9. Future of Patient Self-Testing

7. Immunochemistry Markets

  • 7.1. Market Overview
  • 7.2. Markets for Immunoanalyzer Testing
  • 7.3. Key Players
    • 7.3.1. Abbott Diagnostics
    • 7.3.2. Siemens
    • 7.3.3. Roche
    • 7.3.4. Beckman Coulter, Inc.
    • 7.3.5. bioMérieux
    • 7.3.6. Ortho-Clinical Diagnostics
  • 7.4. Long Term Changes
    • 7.4.1. Key Developments
  • 7.5. Market Drivers and Restraints
  • 7.6. Hot Sectors in the Immunoanalyzer Market
  • 7.7. Key Technologies
    • 7.7.1. Analyzer Integration Chemistry/Immunoassay
    • 7.7.2. Consolidated Workstations
  • 7.8. Key Sector Takeaways

8. Hematology

  • 8.1. Market Overview
  • 8.2. International Markets
    • 8.2.1. U.S. Market
    • 8.2.2. European Market
    • 8.2.3. Asian Market
  • 8.3. Key Players
  • 8.4. Hematology Analyzers
    • 8.4.1. Large Throughput Analyzers
    • 8.4.2. Mid-Size Analyzers
    • 8.4.3. Analyzers for the Small Volume Market
    • 8.4.4. New Hematology Analyzers
  • 8.5. Profitability
  • 8.6. Market Drivers
  • 8.7. Key Sector Takeaways

9. Coagulation

  • 9.1. Market Overview
  • 9.2. International Markets
    • 9.2.1. U.S. Market
    • 9.2.2. European Market
    • 9.2.3. Asian Market
    • 9.2.4. Rest of the World Markets
  • 9.3. Key Players
  • 9.4. Recent Coagulation Testing Sector Activity
    • 9.4.1. Roche and Diagnostica Stago Parting Ways in Laboratory Coagulation
    • 9.4.2. Roche Acquires Verum Diagnostica GmbH and Expands Coagulation Testing Product Line
    • 9.4.3. Universal Biosensors and Siemens Collaborate on Advanced POC Coagulation Platform
    • 9.4.4. Instrumentation Laboratory and Beckman Coulter concluded their Cross-Distribution Agreement
    • 9.4.5. CoaguChek® XS Personal Receives Reimbursement Approval for Self-Testing in Japan
    • 9.4.6. Diagnostica Stago Launches Products for Measurement of Rivaroxaban
    • 9.4.7. Diagnostic Stago Offers Three Factor VII Detection Methods
    • 9.4.8. Diagnostica Stago Offers Three Procoagulant Microparticle Detection Methods
    • 9.4.9. Diagnostica Stago S.A.S enters into Joint Research Agreement with Bristol-Myers Squibb
    • 9.4.10. Trinity Biotech Sold its Worldwide Coagulation Business to the Stago Group
    • 9.4.11. Alere aka Inverness Medical Innovations Acquired HemoSense, Inc.
    • 9.4.12. Alere Announced Positive Results in Clinical Study Evaluating At-Home Coagulation Testing
  • 9.5. Anticoagulation Self-Testing and Self-Management
  • 9.6. Market Drivers and Restraints
    • 9.6.1. Market Drivers
    • 9.6.2. Market Restraints
  • 9.7. Impact of New Oral Anticoagulant Drugs on the Coagulation Testing Market
  • 9.8. Key Technologies
  • 9.9. Key Strategic Recommendations

10. Pathology

  • 10.1. Overview
  • 10.2. Pathology Markets
    • 10.2.1. Market Size
    • 10.2.2. Pathology Markets Served
    • 10.2.3. Key Technologies
  • 10.3. Key Sector Players
    • 10.3.1. Ventana Medical Systems Inc. (part of Roche's Diagnostics Division)
    • 10.3.2. Dako (An Agilent Technologies Company)
    • 10.3.3. Aperio(Part of Leica Biosystems)
    • 10.3.4. Abbott Laboratories
    • 10.3.5. Omnyx, LLC (Part of GE Healthcare)
    • 10.3.6. Visiopharm
  • 10.4. Digital Pathology Markets
    • 10.4.1. Market Drivers in the Digital Pathology Markets
    • 10.4.2. Market Barriers in the Digital Pathology Markets
    • 10.4.3. Digital Pathology Takeaways

11. Microbiology

  • 11.1. Overview
    • 11.1.1. Microbial Culture
    • 11.1.2. Biochemical Tests
  • 11.2. Microscopy
  • 11.3. Microbiology Reagent Market Size and Revenue Analysis
  • 11.4. Key Players
  • 11.5. Diagnostic Platforms for Infectious Diseases
    • 11.5.1. Culture Methods
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Mass Spectroscopy
  • 11.6. Market Drivers and Restraints in Infectious Disease Testing Markets
    • 11.6.1. Market Drivers
    • 11.6.2. Market Restraints
  • 11.7. Key Sector Takeaways

12. Blood Banking and Screening

  • 12.1. Market Overview
  • 12.2. International Markets
  • 12.3. Key Players in Blood Screening

13. Histology and Cytology Tests

  • 13.1. The Overall Market
    • 13.1.1. Market Size
  • 13.2. Market Drivers
  • 13.3. Market Restraints
  • 13.4. Cytology and Histology Technology Platforms
    • 13.4.1. HLA Typing
  • 13.5. Cytology Screening Procedures and Pap Smear Technology
    • 13.5.1. Cytology
    • 13.5.2. Pap Smears
      • 13.5.2.1. Pap Smear Market Share
    • 13.5.3. Detection of HPV
      • 13.5.3.1. Detection of HPV DNA
      • 13.5.3.2. Benefits of Pap Smear and HPV Co-Testing
      • 13.5.3.3. Human Papillomavirus Testing Market Structure
      • 13.5.3.3.1HPV Testing Market Overview
      • 13.5.3.3.2U.S. Market
      • 13.5.3.3.3European Market
      • 13.5.3.3.4Latin American Market
      • 13.5.3.3.5Asian Market
  • 13.6. Histology
    • 13.6.1. IHC Staining
    • 13.6.2. ISH Staining
    • 13.6.3. Special Stains Staining
    • 13.6.4. Tissue Staining Market
    • 13.6.7. Major Players

14. Data Management and Connectivity

  • 14.1. Wireless LANs
  • 14.2. Connectivity Platforms
    • 14.2.1. DataLink Data Management System
      • 14.2.1.1. DataLink Integrated with RALS®-Plus and Quick Multi-Linc
      • 14.2.1.2. DataLink with RALS-Plus
      • 14.2.1.3. DataLink with QML
    • 14.2.2. RALS-Plus, RALS-Web3 and RALS-Freedom
      • 14.2.2.1. International Technidyne Corporation HEMOCHRON Signature Elite
      • 14.2.2.2. Siemens Diagnostics Rapidpoint 500
      • 14.2.2.3. Alere Connect Products
    • 14.2.3. Medical Implant Communications Service (MICS)
    • 14.2.4. Conworx Technology
    • 14.2.5. Alere Informatics
    • 14.2.6. Medasys
    • 14.2.7. NoemaLife
  • 14.3. Advantages of POCT Connectivity
    • 14.3.1. Cost-Benefit Analysis of Testing Devices and IT Connectivity
    • 14.3.2. Hospital Network Issues
  • 14.4. POCT Analyzer Connectivity Software Solutions

15. Company Profiles

  • 15.1. A. Menarini
  • 15.2. Abaxis, Inc.
  • 15.3. Abbott Laboratories
  • 15.4. Accriva Diagnostics, Inc.
  • 15.5. Adaltis
  • 15.6. AdnaGen
  • 15.7. AdvanDx
  • 15.8. Affymetrix, Inc.
  • 15.9. Agendia
  • 15.10. Agilent Technologies
  • 15.11. ALERE, INC.
  • 15.12. Alfa Scientific Designs, Inc.
  • 15.13. Alfa Wasserman, Inc.
  • 15.14. ALPHELYS
  • 15.15. AMS
  • 15.16. Ambry Genetics
  • 15.17. ArcticDx, Inc.
  • 15.18. Ariosa Diagnostics, Inc.
  • 15.19. ARKRAY USA, Inc.
  • 15.20. Asuragen, Inc.
  • 15.21. Atlas Genetics
  • 15.22. Atonomics A/S
  • 15.23. AutoGenomics, Inc.
  • 15.24. Awareness Technology
  • 15.25. Axxin
  • 15.26. Bayer
  • 15.27. BD
  • 15.28. Beckman Coulter Genomics, Inc.
  • 15.29. Biocartis SA
  • 15.30. BioCytex
  • 15.31. Biodata (Microlink Engineering Systems)
  • 15.32. BioData Ltd.
  • 15.33. Biodesix
  • 15.34. BioGenex Laboratories, Inc.
  • 15.35. BioFire Diagnostics, Inc. (Part of bioMérieux now)
  • 15.36. BioMedomics
  • 15.37. bioMérieux
  • 15.38. Biophor Diagnostics
  • 15.39. Bio-Rad
  • 15.40. Biosensia Ltd.
  • 15.41. Biosite Diagnostics (part of Alere)
  • 15.42. Biotage AB
  • 15.43. bioTheranostics
  • 15.44. Cancer Genetics, Inc.
  • 15.45. Caris Life Sciences
  • 15.46. Cepheid
  • 15.47. Celula, Inc.
  • 15.48. Chembio Diagnostics, Inc.
  • 15.49. Clarient
  • 15.50. Coagusense, Inc.
  • 15.51. CombiMatrix Corporation
  • 15.52. Curetis AG
  • 15.53. Cyber Medical Ltd.
  • 15.54. Dako A/S (Agilent Technologies)
  • 15.55. Debiotech
  • 15.56. DexCom
  • 15.57. Diagnostica Stago, Inc.
  • 15.58. Diagnostica Stago S.A.S
  • 15.59. Diagnostics for All
  • 15.60. DiaSorin S.p.A.
  • 15.61. DxNA, LLC.
  • 15.62. Echo Therapeutics
  • 15.63. Eiken Chemical Company Limited
  • 15.64. Enigma Diagnostics Limited
  • 15.65. Epigenomics
  • 15.66. Exact Sciences Corporation
  • 15.67. Exagen Diagnostics, Inc.
  • 15.68. Exiqon
  • 15.69. Exosome Diagnostics
  • 15.70. FIFTY50 Medical, Inc.
  • 15.71. Fluidigm Corporation
  • 15.72. Fujirebio Inc.
  • 15.73. GE Healthcare
  • 15.74. Genera Biosystems
  • 15.75. GenMark Diagnostics, Inc.
  • 15.76. Genomica S.A.U.
  • 15.77. Genomic Health, Inc.
  • 15.78. Genomix Biotech
  • 15.79. Genoptix, Inc.
  • 15.80. Gentag, Inc.
  • 15.81. Great Basin Corporation
  • 15.82. Grifols
  • 15.83. Haemonetics Corporation
  • 15.84. Hologic Gen-Probe
  • 15.85. Hutman Diagnostics, AG
  • 15.86. Hy Laboratories Ltd.
  • 15.87. HYPHEN BioMed
  • 15.88. Ikonisys Inc.
  • 15.89. Illumina, Inc.
  • 15.90. Immunexpress Group
  • 15.91. Infopia Co., Ltd.
  • 15.92. Innovative Biosensors, Inc.
  • 15.93. Integrity Applications
  • 15.94. InterGenetics, Inc.
  • 15.95. Integrated Diagnostics
  • 15.96. International Technidyne Corp (THORATEC CORP
  • 15.97. Instrumentation Laboratory
  • 15.98. IQuum, Inc.(acquired by Roche)
  • 15.99. iSense Corporation (subsidiary of BayerAG)
  • 15.100. JEOL Ltd.
  • 15.101. Johnson & Johnson
  • 15.102. Kommanditgesellschaft Behnk Elektronik GmbH & Co.
  • 15.103. Kyowa Medex
  • 15.104. LabCorp
  • 15.105. Labor BioMedical Technologies GmbH (LABiTec)
  • 15.106. Leica Biosystems
  • 15.107. Life Technologies Corporation
  • 15.108. Luminex Corporation
  • 15.109. Lumora Ltd.
  • 15.110. M-Biotech
  • 15.111. MBio Diagnostics, Inc.
  • 15.112. MDxHealth
  • 15.113. Medica Corporation, Inc.
  • 15.114. Medtronic
  • 15.115. Menssana Research, Inc.
  • 15.116. Meridian Biosciences
  • 15.117. Metaara Medical Technologies Inc.
  • 15.118. Miraculins Inc.
  • 15.119. Mobidiag
  • 15.120. Myriad Genetics, Inc
  • 15.121. Nanosphere
  • 15.122. Nanostring
  • 15.123. Natera Inc.
  • 15.124. Neogenomics
  • 15.125. Nipro Diagnostics
  • 15.126. Nova Biomedical Corporation
  • 15.127. Novartis
  • 15.128. Novo Nordisk
  • 15.129. Nuvera Biosciences
  • 15.130. OraSure
  • 15.131. Ortho Clinical Diagnostics (Formerly a Johnson & Johnson Company)
  • 15.132. Pfizer, Inc.
  • 15.133. Phamatech, Inc.
  • 15.134. Pharma Supply, Inc.
  • 15.135. Polymedco
  • 15.136. Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.)
  • 15.137. Qiagen NV
  • 15.138. Quidel Corporation
  • 15.139. Radient Pharmaceuticals Corporation
  • 15.140. Randox
  • 15.141. Roche AG
  • 15.142. Rosetta Genomics Ltd.
  • 15.143. Sanofi
  • 15.144. Seegene
  • 15.145. Sekisui Diagnostics
  • 15.146. Sensors for Medicine and Science
  • 15.147. Sequenom, Inc.
  • 15.148. Shimadzu Corporation
  • 15.149. Siemens AG
  • 15.150. Siemens Healthcare Diagnostics
  • 15.151. Sienco Inc.
  • 15.152. Simple Diagnostics
  • 15.153. SIRS-Lab
  • 15.154. Smiths Medical
  • 15.155. Source MDx
  • 15.156. Spartan Bioscience
  • 15.157. Spectrum Laboratories, Inc.
  • 15.158. Sysmex America, Inc.
  • 15.159. Technoclone Gmbh
  • 15.160. Telcare
  • 15.161. Thermo Fisher Scientific, Inc.
  • 15.162. TrimGen
  • 15.163. TrovaGene
  • 15.164. Trinity Biotech plc
  • 15.165. U.S. Diagnostics
  • 15.166. Universal Biosensors, Inc.
  • 15.167. Ventana
  • 15.168. VeraLight
  • 15.169. Veredus Laboratories
  • 15.170. Veridex (a Johnson & Johnson company)
  • 15.171. Visiopharm
  • 15.172. Wako
  • 15.173. WILEX AG
  • 15.174. ZS Genetics

INDEX OF FIGURES

  • Figure 2.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2013 and 2018
  • Figure 2.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country, 2013
  • Figure 2.3: Global IVD Market Share by Specialty, 2013
  • Figure 2.4: Indian Diagnostics Market Segments, 2011
  • Figure 2.5: Company Market Share for IVD Testing Markets, 2013
  • Figure 3.1: Percentage Uptake by Analyte in Hospitals Performing POC Testing
  • Figure 3.2: Total Global POCT Market, 2008-2018
  • Figure 3.3: Worldwide Distribution of POCT, 2013
  • Figure 3.4: Summary of Global POCT Markets by Market Segment, 2013
  • Figure 4.1: Global Market for Molecular Diagnostics, 2002-2019
  • Figure 4.2: Market Share by Region for Molecular Diagnostics Testing, 2013
  • Figure 4.3: Key Players Market Share in Global Molecular Diagnostics Testing Markets, 2013
  • Figure 4.4: Share of Molecular Diagnostics Testing by Application, 2013
  • Figure 4.5: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018
  • Figure 4.6: Total Global Infectious Disease Molecular Diagnostics Markets, 2013
  • Figure 4.7: Key Players Market Share in Global Molecular Diagnostics Cancer Testing Markets
  • Figure 4.8: Molecular Diagnostic Markets for Cancer Testing Globally, 2013
  • Figure 4.9: Molecular Diagnostic Markets for Cancer Testing U.S., 2013
  • Figure 5.1: Global Clinical Chemistry Revenues, 2000-2018
  • Figure 5.2: Worldwide Geographical Distribution of Clinical Chemistry Testing, 2013
  • Figure 6.1: Geographic Segments of the Worldwide Glucose Self-Testing Market, 2012 and 2018
  • Figure 6.2: Worldwide Glucose Self-Testing Market by Region, 2018
  • Figure 6.3: Personal Lancet Unit Sales Market Share by Geographic Region, 2013
  • Figure 7.1: Market Share for Key Players in Immunoassay Testing Markets, 2013
  • Figure 9.1: Global Revenue Forecasts for Coagulation Testing, 2010-2018
  • Figure 9.2: U.S. Revenue Forecasts for Coagulation Testing, 2010-2018
  • Figure 9.3: European Revenue Forecasts for Coagulation Testing, 2010-2018
  • Figure 9.4: Japanese Revenue Forecasts for Coagulation Testing, 2010-2018
  • Figure 9.5: ROW Revenue Forecasts for Coagulation Testing, 2010-2018
  • Figure 10.1: Market Shares in Pathology Diagnostics, by Company
  • Figure 10.2: The Global Laboratory Digital Pathology Market, 2012-2018
  • Figure 13.1: Liquid-Based Pap Test Market Share
  • Figure 14.1: The RALS Data Management System Connects to Most of the Major Instruments Used in Point of Care
  • Figure 14.2: AegisPOC Point of Care and Critical Care Connectivity and Information Management System

INDEX OF TABLES

  • Table 2.1: Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018
  • Table 2.2: Global GDP Growth Rates, 2011 to 2015
  • Table 2.3: Top 15 Country Markets for IVD Testing, 2013
  • Table 2.4: Global Distribution of IVD Testing by Market Segments, 2013-2018
  • Table 2.5: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018
  • Table 2.6: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018
  • Table 2.7: Summary of IVD High-Growth Market U.S., 2013
  • Table 2.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018
  • Table 2.9: U.S. Individual IVD High-Growth Markets Revenue Forecast 2008-2018
  • Table 2.10: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.11: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Asia, 2008-2018
  • Table 2.12: Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.13: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018
  • Table 2.14: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018
  • Table 2.16: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.17: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018
  • Table 2.18: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.19: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018
  • Table 2.20: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 2.21: Company Market Share for IVD Testing Markets, 2013
  • Table 2.22: Market Trends in the Diagnostics Space
  • Table 3.1: Summary of Global POCT Markets by Major Market Sub-Segment, 2013 and 2018
  • Table 3.2: Global Company Market Share POCT Analysis, 2013
  • Table 3.3: Main Drivers for the Point of Care Market
  • Table 4.1: Applications of Molecular Diagnostics Technology Platforms
  • Table 4.2: Global Distribution of Molecular Diagnostics Testing by Geographic Region, 2013
  • Table 4.3: Key Players and Market Share in the Global Molecular Diagnostics Testing Market, 2013
  • Table 4.4: Share of Molecular Diagnostics Testing by Application, 2013
  • Table 4.5: Future Areas of Growth in Molecular Diagnostics
  • Table 4.6: Molecular Diagnostics Infectious Disease Market Drivers Ranked in Order of Impact
  • Table 4.7: Molecular Diagnostics Infectious Disease Market Restraints Ranked in Order of Impact
  • Table 4.8: Molecular Diagnostics Infectious Disease Sector: Strategic Recommendations on Business Functions
  • Table 4.9: Nucleic Acid Testing Reagents for HIV Testing
  • Table 4.10: Nucleic Acid Testing Reagents for HBV Testing
  • Table 4.11: Nucleic Acid Testing Reagents for HCV Testing
  • Table 4.12: Molecular Diagnostic Markets for Cancer Testing, 2012
  • Table 4.13: Specific Diagnostic Products Categories Comprising the General Cancer Diagnostic Market
  • Table 4.14: Highlights of the Cancer Molecular Diagnostic Testing Segment
  • Table 4.15: Highlights of Certified Clinical Labs Specializing in Cancer Genetics and Molecular Diagnostic Services
  • Table 4.16: U.S. Market for Molecular Diagnostics Cancer Testing, 2008-2018
  • Table 4.17: Key Diagnostic Company Players and Market Share in Global Molecular Diagnostics Cancer Testing Market
  • Table 4.18: Key Players in the Breast Cancer Molecular Diagnostic Space
  • Table 4.19: Commercially Available Molecular Diagnostic Products for Breast Cancer Assay
  • Table 4.20: Oncotype DX Overview
  • Table 4.21: Comparison of Agendia vs. Genomic Health Breast Cancer Tests
  • Table 4.22: Clarient's Offerings in Breast Cancer Testing
  • Table 4.23: Trends in Cancer Personalized Medicine
  • Table 4.24: Commercial Labs Performing Genetic Testing
  • Table 4.25: Technology Trends in Cancer Testing
  • Table 4.26: Trends in Theranostics
  • Table 4.27: Market Trends in Cancer Testing
  • Table 4.28: Molecular Diagnostics Cancer Market Drivers Ranked in Order of Impact
  • Table 4.29: Molecular Diagnostics Cancer Market Restraints Ranked in Order of Impact
  • Table 5.1: Global Distribution of General Chemistry Testing by Geographic Region, 2013-2018
  • Table 5.2: Leading Marketers of Automated Clinical Chemistry Instruments
  • Table 5.3: Ultra-Large Clinical Chemistry Analyzers
  • Table 5.4: Large Clinical Chemistry Analyzers
  • Table 5.5: Mid-Size Clinical Chemistry Analyzers
  • Table 5.6: Small Clinical Laboratory Analyzers
  • Table 5.7: Clinical Chemistry Analyzer Market Drivers Ranked in Order of Impact
  • Table 5.8: Clinical Chemistry Analyzer Market Restraints Ranked in Order of Impact
  • Table 6.1: Worldwide Comprehensive Glucose Testing Market (Includes Reagents and Supplies in both the Self-Testing and Professional Markets in $ Billions), 2012-2018
  • Table 6.2: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC and POL), 2012-2018
  • Table 6.3: Global Revenues for Professional Point of Care Blood Glucose Monitoring Systems (within Hospitals and Physician's Offices), 2012-2018
  • Table 6.4: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, and Lancets), 2012-2018
  • Table 6.5: Revenues and Market Shares in the SMBG Market in 2013, by Company
  • Table 6.6: Unit Sales of Homecare Lancets in the U.S., 2012-2017
  • Table 6.7: Unit Sales of Homecare Lancets in the E.U., 2012-2017
  • Table 6.8: Dollar Sales of Homecare Lancets in the U.S., 2012-2017
  • Table 6.9: Dollar Sales of Homecare Lancets in the E.U., 2012-2017
  • Table 6.10: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S., 2012-2017
  • Table 6.11: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U., 2012-2017
  • Table 6.12: Competition in the Lancet Market Segment
  • Table 7.1: Global Revenue Forecasts for Immunoanalyzer Testing, 2012-2018
  • Table 7.2: Immunoanalyzer Market Drivers Ranked in Order of Impact
  • Table 7.3: Immunoanalyzer Market Restraints Ranked in Order of Impact
  • Table 8.1: Global Clinical Hematology Analyzer and Reagent Revenues, 2008-2018
  • Table 8.2: Worldwide Distribution of Clinical Hematology Testing Analyzer and Reagent Revenues, 2013
  • Table 8.3 Key Players in Worldwide Hematology Analyzers and Reagent Market
  • Table 8.4: Hematology Analyzers Currently in Market, 2014
  • Table 9.1: Key Players in Anticoagulation Sector
  • Table 9.2: Benefits of Anticoagulation Self-Testing
  • Table 9.3: Barriers to Anticoagulation Self-Testing and Self-Management
  • Table 9.4: Key Market Drivers for Coagulation Testing
  • Table 9.5 Market Drivers for Point of Care Anticoagulation Testing Market
  • Table 9.6 Key Market Restraints for Coagulation Testing
  • Table 9.7: Market Restraints for Point of Care Anticoagulation Testing Market
  • Table 10.1: Global Distribution of Pathology Equipment and Reagents by Geographic Region, 2013-2018
  • Table 10.2: Anatomical Laboratory Computer Systems Manufactures
  • Table 10.3: Digital Pathology Market Drivers Ranked in Order of Impact
  • Table 10.4: Digital Pathology Market Restraints Ranked in Order of Impact
  • Table 11.1: Global Microbiology Reagent Sales 2013-2018
  • Table 11.2: Clinical Microbiology Market Drivers Ranked in Order of Impact
  • Table 11.3: Clinical Microbiology Market Restraints Ranked in Order of Impact
  • Table 12.1: Global Distribution of Blood Banking Reagents Sales by Geographic Region, 2013-2018
  • Table 12.2: Key Players in Blood Banking and Transfusion Markets
  • Table 12.3: Roche's cobas s 201 system: Competitive Advantages
  • Table 12.4: Blood Bank information Systems
  • Table 13.1: Global Histology and Cytology Sales by Segment, 2013-2018
  • Table 13.2: Cytology and Histology Market Drivers Ranked in Order of Impact
  • Table 13.3: Cytology and Histology Market Restraints Ranked in Order of Impact
  • Table 13.4: Estimated Number of Pap Smears Performed by Country, 2013
  • Table 13.5: Global Market for HPV Molecular Diagnostic Testing, 2009-2017
  • Table 13.6: U.S. Market for HPV Diagnostic Testing, 2009-2017
  • Table 13.7: Tissue Diagnostics Market Segments
  • Table 14.1: Applications for Wireless LAN Technology
  • Table 14.2: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 14.3: Applications of RALS Connectivity with POCT Devices
  • Table 15.1: Drugs of Abuse Cut-off Levels for the TOX/See Test by Bio-Rad
  • Table 15.2: OraSure Portfolio of Drugs of Abuse Detection Methodologies
Back to Top